Clinical Trial Update: CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) [Phase 3]

View source ↗

Summary

Phase 3 trial update for Olezarsen (ISIS 678354) in severe hypertriglyceridemia; the CORE-OLE study is currently active but not recruiting participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia

Drugs mentioned

• Olezarsen (olezarsen)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Severe Hypertriglyceridemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING